• Users Online: 865
  • Print this page
  • Email this page
REVIEW
Year : 2023  |  Volume : 6  |  Issue : 1  |  Page : 3-8

Current status of clinical application of immunotherapy in the treatment of glioma: A narrative review


1 Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China
2 INSERM U 1191 – CNRS UMR 5203, University of Montpellier, Montpellier, France

Correspondence Address:
Prof. Jean-Philippe Hugnot
INSERM U 1191 – CNRS UMR 5203, Université de Montpellier, Montpellier 34094
France
Prof. Shengqing Lv
Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), No. 183 Xinqiao Street, Shapingba District, Chongqing 400037
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/glioma.glioma_2_23

Rights and Permissions

Glioma is a common type of brain tumor. Current treatment for glioma includes surgical resection, radiotherapy, chemotherapy, and tumor-treating fields. The application of immunotherapy to treat glioma is still far from satisfactory in the clinic. Here, we review the mechanisms of immunotherapy for glioma (including immune checkpoint inhibitor, chimeric antigen receptor-T-cell, tumor vaccine, and oncolytic virus) and the results of completed clinical trials, and will discuss the current status of immunotherapy and possible future directions.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed613    
    Printed12    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal